Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 9/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | HPGD | P15428 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | GFER | P55789 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 4/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.61 |
| ▸ | RECQL | P46063 | 3/20 | 0.61 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15496394 | 0.95 | MEN1 (0.61) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL13963957 | 0.94 | MEN1 (0.59) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL14494924 | 0.92 | NPC1 (0.60) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL2248723 | 0.90 | MEN1 (0.63) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL7574964 | 0.90 | NPC1 (0.58) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL13963972 | 0.87 | HPSE (0.67) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL15496393 | 0.87 | NPC1 (0.66) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL6322764 | 0.87 | ALDH1A1 (0.76) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL159873 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL30307784 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTNPC1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131007-A1 | METHODS AND COMPOSITIONS FOR PICORNAVIRUS ANTI-VIRAL AGENTS | UNIVERSITY OF CONNECTICUT | 2024-04-25 | — | — | US | disclosed |
| US-10022357-B2 | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease | THE GENERAL HOSPITAL CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20160074367-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE | THE BROAD INSTITUTE, INC. | 2016-03-17 | — | — | US | disclosed |
| WO-2014179303-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYNDROME AND ALZHEIMER'S DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-5468848-A | Disazo dyes for yellow dyes for paper and cellulose | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0632104-A1 | Basic azodyes | BAYER AG (DE) | 1995-01-04 | — | — | EP | disclosed |
| EP-0312838-B1 | BASIC AZODYES, THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1993-09-29 | — | — | EP | disclosed |
| US-4920208-A | YELLOW MONO-AND DISAZO DYES CONTAINING (4-OXY, 6-OXY-OR -THIOCARBONYL-PYRIMIDIN-2-YL)-AMINO GROUPS; COLORFASTNESS; FIBERS; AFFINITY FOR PAPER SURFACE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-04-24 | — | — | US | disclosed |
| EP-0312838-A2 | Basic azodyes, their preparation and their use | BAYER AG (DE) | 1989-04-26 | — | — | EP | disclosed |
| EP-0065595-B1 | WATER-SOLUBLE TRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1986-02-26 | — | — | EP | disclosed |
| US-4544737-A | RED AND ORANGE SHADES ON PAPER | BAYER AKTIENGESELLSCHAFT (DE) | 1985-10-01 | — | — | US | disclosed |
| EP-0057245-B1 | CATIONIC TRIAZINE DYESTUFFS, THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1984-05-30 | — | — | EP | disclosed |
| EP-0065595-A2 | Water-soluble triazine compounds, their preparation and their use | BAYER AG (DE) | 1982-12-01 | — | — | EP | disclosed |
| EP-0057245-A2 | Cationic triazine dyestuffs, their preparation and their use | BAYER AG (DE) | 1982-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022357-B2 | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease | APP, UPF1, BACE1 | ALDH1A1 3698/4885MAPT 17/4885NPC1 1730/4885 |
| US-20240131007-A1 | METHODS AND COMPOSITIONS FOR PICORNAVIRUS ANTI-VIRAL AGENTS | RNASEH1, HNRNPA2B1, HNRNPA1 | ALDH1A1 3057/4885MAPT 3821/4885NPC1 824/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | ALDH1A1 1203/4885MAPT 3113/4885NPC1 2477/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | ALDH1A1 1203/4885MAPT 3113/4885NPC1 2477/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | ALDH1A1 1652/4885MAPT 4858/4885NPC1 3637/4885 |
| US-20160074367-A1 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE | APP, UPF1, GAP43 | ALDH1A1 3791/4885MAPT 50/4885NPC1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.